Effects of Different Vitamin D3 Formulations in Vitamin D-Deficient Adults
The Effects of Eight Weeks of Supplementation With Two Vitamin D₃ Formulations in Adults With Subclinical and Clinical Vitamin D Deficiency: A Randomized Controlled Superiority Pilot Trial
Center for Health Sciences, Serbia
20 participants
Dec 15, 2025
INTERVENTIONAL
Conditions
Summary
This randomized controlled superiority pilot trial will evaluate the efficacy of two vitamin D3 formulations administered over eight weeks in adults with subclinical or clinical vitamin D deficiency. The study will compare changes in serum 25-hydroxyvitamin D concentrations between formulations, as well as the proportion of participants who will achieve vitamin D sufficiency. Both formulations are expected to improve vitamin D status, with the hypothesis that one formulation will demonstrate superior bioavailability, resulting in greater and faster increases in circulating 25-hydroxyvitamin D. The findings will provide preliminary evidence to inform formulation selection and dosing strategies for correcting vitamin D deficiency and will support the design of larger, confirmatory trials.
Eligibility
Inclusion Criteria8
- Adults aged 18 years and over
- Serum 25(OH)D \< 75 nmol/L
- BMI 18.5 - 29.9 kg/m2
- Free of clinically significant acute disorders and severe chronic diseases
- No planned travel to high-UV destinations or tanning bed use during the trial
- Willing to avoid non-study vitamin D supplements
- Able to give written informed consent and comply with study visits
- Submitted informed consent
Exclusion Criteria8
- Pregnancy of breast feeding
- Underweight or obesity
- History of any dietary supplement use within 8 weeks before screening
- Medications that materially alter vitamin D metabolism or calcium balance
- Subjects with a history of medicine or alcohol abuse
- Abnormal values for lab clinical chemistry (\> 2 SD)
- Unwillingness to return for follow-up analysis
- Participation in other clinical trials within 60 days prior to screening
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Active powdered ingredient (2,000 IU/d)
Active oily ingredient (2,000 IU/d)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07317830